Immunome, Inc. (IMNM) Stock Price

IMNMStock

$16.47−0.12%52W

Market Cap$1.94B

P/E—

PEG Ratio—

Div yield—

Beta2.67

IMNM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-37.98%

Price vs S&P 500 (4W)-32.98%

VGM Score24.32

Book Value / Share (Quarterly)$4.63

P/TBV (Annual)20.53x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.01

Price vs S&P 500 (YTD)-35.25%

Net Profit Margin (TTM)-1687.08%

EPS (TTM)$-2.51

10-Day Avg Trading Volume1.49M

EPS Excl Extra (TTM)$-2.51

EPS (Annual)$-2.43

ROI (Annual)-33.48%

Cash / Share (Quarterly)$4.59

ROA (Last FY)-31.09%

Revenue Growth TTM (YoY)-63.29%

EBITD / Share (TTM)$-2.62

ROE (5Y Avg)-111.44%

Operating Margin (TTM)-1784.14%

Cash Flow / Share (Annual)$-1.83

P/B Ratio3.70x

P/B Ratio (Quarterly)4.57x

Net Income / Employee (Annual)$-1,815,300

EV / Revenue (TTM)137.09x

Net Interest Coverage (TTM)-2470.00x

ROA (TTM)-46.93%

EPS Incl Extra (Annual)$-2.43

Current Ratio (Annual)14.69x

Quick Ratio (Quarterly)14.56x

3-Month Avg Trading Volume1.37M

52-Week Price Return-0.12%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.50

P/S Ratio (Annual)280.00x

Asset Turnover (Annual)0.01x

52-Week High$30.06

EPS Excl Extra (Annual)$-2.43

CapEx CAGR (5Y)93.32%

26-Week Price Return-28.08%

Quick Ratio (Annual)14.53x

13-Week Price Return-26.21%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)15.08x

Enterprise Value$1.73B

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)7.59%

Revenue / Employee (Annual)$59,300

Pretax Margin (Annual)-3059.99%

Cash / Share (Annual)$5.78

3-Month Return Std Dev54.94%

Net Income / Employee (TTM)$-2,173,700

ROE (Last FY)-33.48%

Net Interest Coverage (Annual)-784.00x

EPS Basic Excl Extra (Annual)$-2.43

P/FCF (TTM)128.80x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.51

ROI (TTM)-50.56%

P/S Ratio (TTM)154.38x

Revenue / Share (Annual)$0.08

Tangible BV / Share (Annual)$1.37

Price vs S&P 500 (52W)-15.65%

Year-to-Date Return-23.32%

5-Day Price Return-13.99%

EPS Normalized (Annual)$-2.43

ROA (5Y Avg)-84.20%

Net Profit Margin (Annual)-3059.99%

Month-to-Date Return-23.43%

Cash Flow / Share (TTM)$-1.77

EBITD / Share (Annual)$-2.54

Operating Margin (Annual)-3228.83%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-111.44%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.51

P/TBV (Quarterly)56.26x

P/B Ratio (Annual)3.74x

Pretax Margin (TTM)-1687.08%

Book Value / Share (Annual)$5.61

Price vs S&P 500 (13W)-28.90%

Beta2.67x

Revenue / Share (TTM)$0.00

ROE (TTM)-50.56%

52-Week Low$14.64

vGradeF

gGradeF

mGradeC

vgmGradeD

IMNM Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.50	-$0.65	-28.78%(-$0.15)
Q4 2025	Mar 3, 2026	-$0.57	-$0.76	-32.80%(-$0.19)
Q3 2025	Nov 6, 2025	-$0.54	-$0.65	-19.63%(-$0.11)
Q2 2025	Aug 6, 2025	-$0.50	-$0.50	-0.29%(-$0.00)

IMNM Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.24

4.20

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IMNMImmunome, Inc.	F	F	C	154.4x	-63.3%	—	—	$16.47
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Immunome, Inc.

Immunome Inc is a targeted oncology company advancing antibody-drug conjugates and radioligand therapies. Its lead program, varegacestat, demonstrated positive Phase 3 results in desmoid tumors, with additional programs including the Phase 1-stage ROR1 ADC IM-1021 and IND-cleared FAP-targeted radioligand IM-3050. The company maintains a preclinical portfolio of solid tumor ADCs.

IMNM Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.59

Revenue estimate$133,330

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

IMNM Insider Transactions

SellSep 11, 2026
HIGGINS JACK
Officer
Shares: 13,200Value: $334,224
SellAug 12, 2026
BARCHAS ISAAC
Director
Shares: 83,464Value: $2.20M
SellAug 7, 2026
BARCHAS ISAAC
Director
Shares: 36,088Value: $940,453
SellAug 4, 2026
HORN KINNEY
Officer
Shares: 90,616Value: $2.27M

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals
STDNStandard Nuclear, Inc.Industrial Chemicals
TRLVTrulieve Cannabis Corp.Pharmaceutical Preparations
CCThe Chemours CompanyChemicals
RXRXRecursion Pharmaceuticals, Inc. Class A Common StockBiological Products
NVAXNovavax IncBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$14.64

High$30.06